## CORRECTION

# Correction: Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study

Sarah Djabarouti*[1], Dominique Breilh[1], Pierre Duffau[2], Estibaliz Lazaro[2], Carine Greib[2], Olivier Caubet[2], Marie-Claude Saux[1], Jean-Luc Pellegrin[2] and Jean-François Viallard[2]

See related research by Djabarouti *et al.*, http://arthritis-research.com/content/12/6/R217

After publication of our recent article [1], we noticed an error in the unit for the area under the time-concentration curve between 0 and 12 hours ($AUC_{0-12h}$). Throughout the article and table 1 the unit should be mg·h/L (mg multiplied by hour per L) not mg/hour/L .

The correct table is given here as Table 1.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
[1]Laboratoire de Pharmacocinétique et Pharmacie Clinique EA2968, Université Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, CHU de Bordeaux, Avenue de Magellan, 33604 Pessac Cedex, France. [2]Service de Médecine Interne et des Maladies Infectieuses, Université Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, CHU de Bordeaux, Avenue de Magellan, 33604 Pessac Cedex, France.

**Reference**
1.  Djabarouti S, Breilh D, Duffau P, Lazaro E, Greib C, Caubet O, Saux MC, Pellegrin JL, Viallard JF: **Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.** *Arthritis Res Ther* 2010, **12**:R217

*Correspondence: sarah.djabarouti@chu-bordeaux.fr
[1]Laboratoire de Pharmacocinétique et Pharmacie Clinique EA2968, Université Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, CHU de Bordeaux, Avenue de Magellan, 33604 Pessac Cedex, France
Full list of author information is available at the end of the article

**Table 1. Inclusion characteristics (of the 26 systemic lupus erythematosus patients) and their ability to predict clinical outcome (univariate analysis)**

| Inclusion characteristic | Total $n = 26$ | Successes $n = 17$ | Failures $n = 8$ | P value[a] |
|---|---|---|---|---|
| Demographic | | | | |
| Females/Males, number | 16/10 | 12/5 | 4/4 | 0.28[b] |
| Age, years | 46 (35-61)[a] | 46.5 (35-61) | 46 (38-61) | 0.9 |
| Body weight, kg | 60 (56-75) | 60 (56-75) | 62 (58-82.5) | 0.62 |
| Disease | | | | |
| Duration before entry, months | 11 (7-14) | 11 (7-12) | 10 (6-13) | 0.30 |
| SLEDAI score | 0 (0-2) | 0 (0-2) | 0 (0-2) | 0.20 |
| C3, g/L | 1 (0.6-1.1) | 1 (0.9-1.1) | 0.8 (0.56-0.96) | 0.21 |
| C4, g/L | 0.2 (0.1-0.2) | 0.2 (0.1-0.2) | 0.2 (0.16-0.24) | 0.78 |
| Anti-double-stranded DNA, IU/mL | 24 (6-51) | 8 (1 -32) | 38 (9 -55) | 0.19 |
| Biological | | | | |
| GFR, mL/minute | 95 (67-125) | 95 (67-125) | 93.5 (76-109) | 0.64 |
| Albumin, g/L | 40 (39.8-43.8) | 40 (37.9-43.8) | 42.8 (40-46.9) | 0.33 |
| Aspartate aminotransferase, IU/L | 23 (19-26) | 23 (17.5-24.5) | 28 (20-33) | 0.26 |
| Alanine aminotransferase, IU/L | 22 (15-29) | 19 (13-24.5) | 25 (19-37) | 0.21 |
| $\gamma$-Glutamyltransferase, IU/L | 24 (17-63) | 23 (17-21) | 42 (17-61) | 0.92 |
| Treatment | | | | |
| MMF, g/day | 2 (2-2) | 2 (2-2) | 2 (2-2) | 0.9 |
| Corticosteroids, mg/day | 11 (7-35) | 10 (5-20) | 15 (7-45) | 0.37 |
| Months of MMF therapy | 2 (1-3) | 2 (1-3) | 2 (1-3) | 0.56 |
| Months of corticosteroids | 10 (6-13) | 10 (5-15) | 9 (5-14) | 0.12 |
| MPA pharmacokinetic parameters | | | | |
| $AUC_{0-12 h}$, mg·hour/L | 64.7 (38.2-82) | 73.1 (61.8-95) | 37.7 (32-43.7) | 0.003 |
| $C_{max}$, mg/L | 16.1 (9.5-18.5) | 16.3 (9.7-17.4) | 13.3 (7-22.5) | 0.69 |
| $T_{max}$, hours | 1 (1-2) | 1 (1-2) | 1.1 (1-2) | 0.82 |
| $C_{12 h}$, mg/L | 2.4 (1.5-4.1) | 3.7 (2.3-4.9) | 1.5 (0.6-2.1) | 0.008 |
| MPAG pharmacokinetic parameters | | | | |
| $AUC_{0-12 h}$, mg·hour/L | 775.3 (475-1,026) | 791 (635-1,166) | 678.8 (426-840.6) | 0.22 |
| $T_{max}$, hours | 2 (2-3) | 2.3 (2-3) | 1.3 (1-2) | 0.01 |
| $C_{12 h}$, mg/L | 32.1 (24.3-41.9) | 34.7 (26.4-49.2) | 29.8 (15.5-40) | 0.26 |
| MPAG/MPA $AUC_{0-12 h}$ ratio | 11.5 (8.3-20.7) | 10.9 (6.2-14.8) | 18.7 (14.1-22.7) | 0.07 |
| MPAG/MPA $C_{12 h}$ ratio | 11.5 (6.8-17.3) | 10.2 (6.3-15) | 18.7 (11.5-47.2) | 0.02 |

Values are expressed as median (interquartile range) unless stated otherwise. [a]Mann-Whitney *U* test; [b]Fisher exact test. $AUC_{0-12 h}$, area under the plasma concentration-versus-time curves for hours 0 to 12; $C_{12 h}$, 12-hour trough concentration; $C_{max}$, maximal concentration; GFR, glomerular filtration rate (estimated with the Cockcroft-Gault formula); MMF, mycophenolate mofetil; MPA, mycophenolic acid; MPAG, mycophenolic acid glucuronide; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; $T_{max}$, time to maximal concentration.